obesity drug news today glp-1 2025 sep 30 Market Size to Hit USD 66.57 Billion by 2035 Alarming rise in weight loss

This patient information is based on a leaflet from the Faculty of Sexual and Reproductive Healthcare (FSRH) and the Primary Care Womens Health Society

For employers and insurers, the initial question was whether to cover GLP-1s for obesity, said Virta CEO Sami Inkinen

Because of these broad effects, we wanted to see whether they would reduce all-cause mortality compared with another more weight-neutral diabetes medication. Mavromatis and colleagues conducted an observational study in which they used the Optum database to identify 170,030 adults (mean age, 56.8 years

The DURATION-8 trial (N=695) evaluated exenatide once weekly plus dapagliflozin and found additive HbA1c reduction (1.5% versus 1.0% for either monotherapy) without increased hypoglycemia [15]

Our guide on Washington Medicare & Medicaid Changes for 2026 covers how these programs interact and what changed this year for dual-eligible beneficiaries